海王生物(000078) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥8,087,937,989.71, a decrease of 18.78% compared to ¥9,957,850,383.56 in the same period last year[5] - Net profit attributable to shareholders was ¥42,641,426.53, down 42.79% from ¥74,530,706.41 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0162, a decline of 40.22% compared to ¥0.0271 in the same period last year[5] - Net profit for Q1 2024 was CNY 69,171,556.13, a decline of 37.2% from CNY 110,250,475.24 in Q1 2023[19] - Earnings per share for Q1 2024 were CNY 0.0162, compared to CNY 0.0271 in Q1 2023, reflecting a decrease of 40.3%[19] Cash Flow - The net cash flow from operating activities decreased by 48.16% to ¥56,755,485.31 from ¥109,477,986.68 in the previous year[5] - The company’s cash flow from operating activities showed a decline, indicating potential challenges in maintaining liquidity[20] - The net cash flow from operating activities for Q1 2024 was ¥56,755,485.31, a decrease of 48% compared to ¥109,477,986.68 in Q1 2023[21] - The net cash flow from financing activities was -¥57,851,412.93, contrasting with a positive net cash flow of ¥121,377,969.99 in Q1 2023[22] - The company reported a net cash increase of -¥34,279,836.16 for Q1 2024, compared to an increase of ¥178,380,466.94 in Q1 2023[22] Assets and Liabilities - Total assets increased by 1.11% to ¥32,662,246,219.97 from ¥32,304,686,545.78 at the end of the previous year[5] - The total liabilities as of Q1 2024 amounted to CNY 28,406,589,344.62, an increase from CNY 28,087,241,284.03 in the previous year[16] - The total equity attributable to shareholders of the parent company was CNY 3,045,564,067.12, up from CNY 3,002,922,640.59 in Q1 2023[16] Operating Costs and Expenses - Total operating costs for Q1 2024 were CNY 7,981,269,889.39, down 18.7% from CNY 9,825,719,310.45 in the same period last year[17] - Research and development expenses for Q1 2024 were CNY 10,122,756.35, slightly down from CNY 11,339,139.83 in Q1 2023[17] - The company reported a decrease in sales expenses to CNY 282,240,166.46 from CNY 419,809,578.57 in the same quarter last year, a reduction of 32.8%[17] Investments and Receivables - Long-term receivables increased by 52.77% due to changes in the collection cycle of subsidiary payments[10] - Prepayments rose by 75.51%, primarily due to an increase in equipment leasing payments received by subsidiaries[10] - The company experienced a 130.40% decrease in investment income, attributed to reduced disposal gains from subsidiaries[10] - Long-term equity investments remained stable at RMB 188,513,324.04, showing minimal change from RMB 188,461,054.75[15] - Accounts receivable stood at RMB 17,364,050,205.10, slightly up from RMB 17,356,877,098.26, indicating a marginal increase[15] Cash and Equivalents - The company's cash and cash equivalents increased to RMB 3,769,210,852.99 from RMB 3,480,400,987.64, reflecting a growth of approximately 8.3%[15] - The total cash and cash equivalents at the end of Q1 2024 stood at ¥1,102,450,212.12, slightly down from ¥1,140,882,786.80 at the end of Q1 2023[22] - Cash received from sales and services in Q1 2024 was CNY 8,348,547,159.91, down from CNY 8,938,394,583.73 in Q1 2023[20] Strategic Initiatives - The company plans to transfer 275,083,326 shares, equivalent to 10% of its total share capital, to Guangdong Silk and Textile Group Co., Ltd.[12] - The management is actively engaging with stakeholders to discuss the progress of the planned share transfer and other strategic initiatives[13] - The company is committed to adhering to legal and regulatory requirements regarding the disclosure of significant matters[13]